Drilldown: Medicines

Other values:

Search

None (87) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Spravato (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (90) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (90) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (90) · 28 mg/device (each dose uses 2 devices) (1)

None (90) · 84 mg per session (1)

None (89) · Intranasal (under direct medical supervision) (1) · Oral (1)

None (89) · 30–60 minutes (1) · Within hours of first administration (1)

None (88) · 8–12 hours (1) · About 20 minutes (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (88) · 3–5 hours (1) · 9–12 minutes (intravenous) (1) · ~7-12 hours (1)

None (89) · 70–90% (oral) (1) · ~48% intranasal (1)

None (89) · Avoid; may cause fetal harm (1) · Not established (1)

None (88) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)